Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US

被引：0
|
作者：
Cohen, Joshua M. [1 ]
Thompson, Stephen [1 ]
Patterson-Lomba, Oscar [2 ]
Driessen, Maurice [3 ]
Seminerio, Michael [1 ]
Carr, Karen [1 ]
Mu, Fan [2 ]
机构：
[1] Teva Branded Pharmaceut Prod R&D Inc, Petah Tiqwa, Israel
[2] Anal Grp, Boston, MA USA
[3] Teva Pharmaceut, Petah Tiqwa, Israel
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
4171
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Fremanezumab for the prevention of chronic and episodic migraine
    Lionetto, L.
    Cipolla, F.
    Guglielmetti, M.
    Martelletti, P.
    [J]. DRUGS OF TODAY, 2019, 55 (04) : 265 - 276
  • [42] Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
    Ashina, Messoud
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Du, Evelyn
    [J]. HEADACHE, 2021, 61 (06): : 916 - 926
  • [43] Real-world reductions in migraine-related healthcare resource utilization and medication use with fremanezumab treatment in US migraine patients using concomitant acute gepants
    Eugeni, P.
    Rooney, M. E.
    Saikali, N. P.
    Niu, Z.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    McVige, J. W.
    [J]. HEADACHE, 2022, 62 : 158 - 158
  • [44] Real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab
    Yuan, H.
    Hopkins, M.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    Marmura, M. J.
    [J]. HEADACHE, 2022, 62 : 156 - 157
  • [45] REAL-WORLD REDUCTIONS IN MIGRAINE-RELATED HEALTH CARE RESOURCE UTILIZATION AND COSTS FOR PATIENTS INITIATING FREMANEZUMAB: A 12-MONTH RETROSPECTIVE US CLAIMS ANALYSIS
    Driessen, M. T.
    Krasenbaum, L. J.
    Ramirez-Campos, V
    DiEgidio, R.
    Tian, M.
    Seminerio, M. J.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S346 - S346
  • [46] Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine
    Brandes, Jan Lewis
    Kudrow, David
    Yeung, Paul P.
    Sakai, Fumihiko
    Aycardi, Ernesto
    Blankenbiller, Tricia
    Grozinski-Wolff, Melissa
    Yang, Ronghua
    Ma, Yuju
    [J]. CEPHALALGIA, 2020, 40 (05) : 470 - 477
  • [47] Fremanezumab Increases the Maximum Number of Consecutive Headache Free Days for Patients with High Frequency Episodic Migraine
    Noble, R.
    Aycardi, E.
    Bigal, M.
    McDonald, M.
    Loupe, P.
    [J]. HEADACHE, 2017, 57 : 185 - 185
  • [48] Fremanezumab increases the maximum number of consecutive headache free days for patients with high frequency episodic migraine
    Noble, Robert
    Aycardi, Ernesto
    Bigal, Marcelo
    McDonald, Mirna
    Loupe, Pippa
    [J]. JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [49] Real-world migraine-related health care resource utilization and costs for patients initiating fremanezumab: A US retrospective claims analysis
    Buse, D. C.
    Seminerio, M. J.
    Tangirala, K.
    Thompson, S. F.
    Ariely, R.
    Cohen, J. M.
    Carr, K.
    [J]. HEADACHE, 2021, 61 : 71 - 72
  • [50] REDUCTIONS IN MIGRAINE FREQUENCYAND DURATION IN PATIENTS WITH CHRONIC MIGRAINE TREATED WITH ERENUMAB: INTERIM RESULTS FROM A REAL-WORLD MULTICENTER CHART-REVIEW STUDY OF US HEADACHE CENTERS
    Faust, Elizabeth
    Pivneva, Irina
    Yang, Karen
    Betts, Keith A.
    Ahmed, Zubair
    Hogan, Rebecca
    Blumenfeld, Andrew
    Schim, Jack
    Feoktistov, Alexander
    Carnes, Kenneth
    Bensink, Mark
    Wu, Eric Q.
    Chou, Denise E.
    Chandler, David
    [J]. CEPHALALGIA, 2020, 40 : 18 - 19
12345